Literature DB >> 12395326

Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS.

Steven W M Olde Damink1, Rajiv Jalan, Doris N Redhead, Peter C Hayes, Nicolaas E P Deutz, Peter B Soeters.   

Abstract

Ammonia is central to the pathogenesis of hepatic encephalopathy. This study was designed to determine the quantitative dynamics of ammonia metabolism in patients with cirrhosis and previous treatment with a transjugular intrahepatic portosystemic stent shunt (TIPSS). We studied 24 patients with cirrhosis who underwent TIPSS portography. Blood was sampled and blood flows were measured across portal drained viscera, leg, kidney, and liver, and arteriovenous differences across the spleen and the inferior and superior mesenteric veins. The highest amount of ammonia was produced by the portal drained viscera. The kidneys also produced ammonia in amounts that equaled total hepatosplanchnic area production. Skeletal muscle removed more ammonia than the cirrhotic liver. The amount of nitrogen that was taken up by muscle in the form of ammonia was less than the glutamine that was released. The portal drained viscera consumed glutamine and produced ammonia, alanine, and citrulline. Urea was released in the splenic and superior mesenteric vein, contributing to whole-body ureagenesis in these cirrhotic patients. In conclusion, hyperammonemia in metabolically stable, overnight-fasted patients with cirrhosis of the liver and a TIPSS results from portosystemic shunting and renal ammonia production. Skeletal muscle removes more ammonia from the circulation than the cirrhotic liver. Muscle releases excessive amounts of the nontoxic nitrogen carrier glutamine, which can lead to ammonia production in the portal drained viscera (PDV) and kidneys. Urinary ammonia excretion and urea synthesis appear to be the only way to remove ammonia from the body.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395326     DOI: 10.1053/jhep.2002.36497

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

Review 1.  Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

Authors:  Amit S Seyan; Robin D Hughes; Debbie L Shawcross
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

Review 2.  Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives.

Authors:  Milan Holecek
Journal:  Metab Brain Dis       Date:  2013-08-31       Impact factor: 3.584

3.  Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.

Authors:  Vanessa Stadlbauer; Josef Tauss; Horst R Portugaller; Philipp Stiegler; Florian Iberer; Rudolf E Stauber
Journal:  Metab Brain Dis       Date:  2006-12-14       Impact factor: 3.584

Review 4.  Dietary and nutritional indications in hepatic encephalopathy.

Authors:  Manuela Merli; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2008-12-04       Impact factor: 3.584

5.  The liver, the brain and nitrogen metabolism.

Authors:  Piero Amodio
Journal:  Metab Brain Dis       Date:  2008-12-24       Impact factor: 3.584

Review 6.  The treatment of hepatic encephalopathy.

Authors:  Marsha Y Morgan; A Blei; K Grüngreiff; R Jalan; G Kircheis; G Marchesini; O Riggio; Karin Weissenborn
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 7.  Branched-chain amino acids for people with hepatic encephalopathy.

Authors:  Lise Lotte Gluud; Gitte Dam; Iñigo Les; Giulio Marchesini; Mette Borre; Niels Kristian Aagaard; Hendrik Vilstrup
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

Review 8.  New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Authors:  Luisa Baker; Bernard Lanz; Fausto Andreola; Javier Ampuero; Anisha Wijeyesekera; Elaine Holmes; Nicolaas Deutz
Journal:  Metab Brain Dis       Date:  2016-09-30       Impact factor: 3.584

9.  Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.

Authors:  Manuela Merli; Michela Giusto; Cristina Lucidi; Valerio Giannelli; Ilaria Pentassuglio; Vincenza Di Gregorio; Barbara Lattanzi; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2012-12-07       Impact factor: 3.584

Review 10.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.